P51 | EVOLVING ATTRITION RATES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE OVER A 30-YEARS PERIOD FROM A SINGLE CENTER EXPERIENCE
Therapeutic innovation in multiple myeloma (MM), through the sequential integration of immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, cellular therapies, and bispecific antibodies, has significantly improved survival outcomes. Alongside novel agents and combinations, optimize...
Zapisane w:
| Główni autorzy: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Ferrata Storti Foundation
2026-04-01
|
| Seria: | Haematologica |
| Dostęp online: | https://haematologica.org/article/view/14086 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|